Stay up to date

THEME FOR ICASA 2021 - "Africa’s AIDS response: The race to 2030 – Evidence. Scale Up. Accelerate"

OBJECTIVES FOR ICASA 2021 -

• To strengthen health systems to integrate high impact interventions on comorbidities, emerging infections and NCDs.
• To build, strengthen and invest in Africa’s scientific capacity and manufacturing of vaccines, diagnostics and therapeutics.
• To Identify in Africa, resource tailored interventions for populations most affected including women, children, adolescents, men and Key Populations.
• To evaluate the impact of COVID-19 on the HIV/AIDS response and share lessons learned in overcoming barriers in maintaining continuity of care for people living with and at risk for HIV infection.
• To amplify national, regional, continental and global integration to reach epidemic control in Africa: Contributions from Africans in the Diaspora.

Regular Registration for ICASA2021, Durban-South Africa is still open.
Register from today till 31st August 2021 and save 100USD.

For more information visit http://icasa2021.saafrica.org/

Another CEPI partner, Clover Biopharmaceuticals, has become the latest vaccine developer to sign an advance purchase agreement with COVAX to make their COVID-19 vaccine available to populations worldwide.
Under the new agreement between Clover and our COVAX partner, Gavi, up to 414 million doses are set to be made available to participating countries in 2021 and 2022. CEPI’s significant early investments have been critical to the development of Clover’s vaccine candidate, and were directly linked to access commitments which enabled this deal.

Since late Spring, 2020, CEPI has provided up to $328 million to support preclinical and clinical testing of the candidate vaccine, in addition to scaling-up the biotech’s in-house manufacturing capacity. Clover yesterday announced that its pivotal global Phase 2/3 clinical trial—funded by CEPI—is now fully enrolled, and that interim efficacy data is expected in Q3.
COVAX has now distributed over 100 million vaccines since its launch in February this year. Supply of Clover’s vaccine is anticipated to start in the last quarter of the year, pending Emergency Use Licensure from the World Health Organization (WHO).

To learn more visit https://cepi.net/news_cepi/from-lab-to-potential-jab-clovers-covid-19-vaccine-story/

This year’s edition of INTEREST will be held as a virtual meeting from 12 – 14 October. Dr. Andrew Kambugu, a member of the International Conference Committee (ICC), shares his thoughts on why you should join this important meeting.

Young Investigators
The registration fee is waived for all Young Investigators. To be eligible as a young investigator, one should be:
- 35 years of age or younger; and
- a current Master/PhD student OR have obtained an MD/PharmD/PhD degree in the last five years.
An application form needs to be completed by a supervisor and received by the Conference Secretariat at Lara.daSilvaMiguel@amededu.com.

Resource-Limited Settings
In addition, we are pleased to provide a discounted registration fee for all healthcare professionals, NGO/GO representatives, and advocates from resource-limited settings. This is available when completing the registration

For more information visit http://interestconference.org/